Enzalutamide versus abiraterone as a first-line endocrine therapy for castration-resistant prostate cancer (ENABLE study for PCa): a study protocol for a multicenter randomized phase III trial

[1]  H. Ikeda,et al.  The relationship between prostate‐specific antigen and TNM classification or Gleason score in prostate cancer patients with low prostate‐specific antigen levels , 2015, The Prostate.

[2]  Hiroshi Nishimoto,et al.  An updated report on the trends in cancer incidence and mortality in Japan, 1958-2013. , 2015, Japanese journal of clinical oncology.

[3]  F. Saad,et al.  Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. , 2015, The Lancet. Oncology.

[4]  F. Saad,et al.  Enzalutamide in metastatic prostate cancer before chemotherapy. , 2014, The New England journal of medicine.

[5]  Chiung-Kuei Huang,et al.  Outcomes and predictive factors of prostate cancer patients with extremely high prostate-specific antigen level , 2014, Journal of Cancer Research and Clinical Oncology.

[6]  K. Izumi,et al.  Optimal treatment for castration-resistant prostate cancer , 2014, Asian journal of andrology.

[7]  O. Sartor,et al.  Treatment sequencing in metastatic castrate-resistant prostate cancer , 2014, Asian journal of andrology.

[8]  I Syndikus,et al.  Alpha emitter radium-223 and survival in metastatic prostate cancer. , 2013, The New England journal of medicine.

[9]  K. Nakajima,et al.  Bone scintigraphy as a new imaging biomarker: the relationship between bone scan index and bone metabolic markers in prostate cancer patients with bone metastases , 2013, Annals of Nuclear Medicine.

[10]  K. Katanoda,et al.  An updated report of the trends in cancer incidence and mortality in Japan. , 2013, Japanese journal of clinical oncology.

[11]  F. Saad,et al.  Abiraterone in metastatic prostate cancer without previous chemotherapy. , 2013, The New England journal of medicine.

[12]  Hiroyuki Takahashi,et al.  Tri-Modality therapy with I-125 brachytherapy, external beam radiation therapy, and short- or long-term hormone therapy for high-risk localized prostate cancer (TRIP): study protocol for a phase III, multicenter, randomized, controlled trial , 2012, BMC Cancer.

[13]  K. Izumi,et al.  Increases in bone turnover marker levels at an early phase after starting zoledronic acid predicts skeletal‐related events in patients with prostate cancer with bone metastasis , 2012, BJU international.

[14]  K. Izumi,et al.  Ethinylestradiol improves prostate-specific antigen levels in pretreated castration-resistant prostate cancer patients. , 2010, Anticancer research.

[15]  J. Machiels,et al.  Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial , 2010, The Lancet.

[16]  P. Kantoff,et al.  Sipuleucel-T immunotherapy for castration-resistant prostate cancer. , 2010, The New England journal of medicine.

[17]  H. Scher,et al.  Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate Cancer , 2009, Science.

[18]  Susan Halabi,et al.  Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  Kenya Yamaguchi,et al.  Prospective Study of Estramustine Phosphate for Hormone Refractory Prostate Cancer Patients following Androgen Deprivation Therapy , 2005, Urologia Internationalis.

[20]  V. Hasselblad,et al.  Systematic review and meta‐analysis of monotherapy compared with combined androgen blockade for patients with advanced prostate carcinoma , 2002, Cancer.

[21]  N Nonomura,et al.  Potential mechanism for the effects of dexamethasone on growth of androgen-independent prostate cancer. , 2001, Journal of the National Cancer Institute.

[22]  Crawford,et al.  Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials , 2000, The Lancet.

[23]  K. Pienta,et al.  Rapid ("warm") autopsy study for procurement of metastatic prostate cancer. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[24]  M. Rowlands,et al.  Novel steroidal inhibitors of human cytochrome P45017 alpha (17 alpha-hydroxylase-C17,20-lyase): potential agents for the treatment of prostatic cancer. , 1995, Journal of medicinal chemistry.

[25]  A. Jemal,et al.  Cancer statistics, 2016 , 2016, CA: a cancer journal for clinicians.

[26]  O. Sartor,et al.  Effect of prednisone on prostate-specific antigen in patients with hormone-refractory prostate cancer. , 1998, Urology.

[27]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.